Recent studies have revealed that ADAM9 promotes tumor progression by protecting KRAS from lysosomal degradation and reducing its interaction with plasminogen activator inhibitor-1 (PAI-1) and microtubule-associated protein 1 light chain 3 (LC3) (77). Here, MAP1LC3A is linked to neoplasm.